CoVICIS – EU-Africa Concerted Action on SAR-CoV-2 Virus Variant and Immunological Surveillance

CoVICIS has a global approach coupling state-of-the-art virologic and immunologic platforms with large genomic surveillance studies and diverse cohorts in EU and SSA.
CoVICIS aims to contribute to the early identification of emerging VOC and addresses key unanswered questions regarding the susceptibility to infection with VOC, the risk posed by VOC in immunocompromised patients, and the modalities of infection and immune responses in children.

Details

Status:

  • active

Research Focus:

  • Medicine and Health

Project Coordination:

Centre Hospitalier Universitaire Vaudois
(CHUV)

Partners:

Hospital Centre Vaudois University, Switzerland
Ecole Polytechnique Federale de Lausanne, Switzerland
Eurovacc Foundation, Switzerland
University of Geneva, Switzerland
University of Zurich, Switzerland
National Institute of Health and Medical Research, France
University of Milan, Italy
Stitching International Aids Vaccines, The Netherlands

Countries:

Germany (Bavaria), Ethiopia, South Africa

Funding Agency:

European Union (EU)

Funding Type:

Horizon Europe (HEU)

Duration:

01/11/2021
– 30/04/2025

Budget:

€ 10 048 971,68 EUR

URL: